New stock first day | Kingway Pharmaceuticals-B (02595) debuted on the market with an opening increase of 115.79% in the morning session. Its core product GFH925 has already been commercialized domestically.

Jingfang Medicine-B (02595) debuted on the stock market. The announcement showed that the price per share was 20.39 HKD, with a total issuance of 89.24 million shares. Each board lot consists of 200 shares, and the net proceeds amount to approximately 1.669 billion HKD. As of the time of publication, the stock has risen by 115.79%, reaching 44 HKD, with a trading volume of 491 million HKD. Public information shows that Jingfang Medicine focuses on the development of new treatment solutions in the areas of oncology (covering different treatment lines for various solid tumors) as well as autoimmune and inflammatory diseases. The company has established a product pipeline, including 8 candidate products, with 5 in the clinical development stage, including two core products, GFH925 and GFH375. GFH925 is the first approved KRAS G12C inhibitor in China and the third globally. It was approved by the National Medical Products Administration in August 2024 for the treatment of non-small cell lung cancer (NSCLC). Currently, a Phase II study, KORCUS, is being conducted in the European Union. GFH375 is an oral KRAS G12D inhibitor undergoing Phase II clinical trials in China. The company has reached authorization agreements with Verastem for three candidate products, including GFH375, granting them development and commercialization rights outside the Greater China region.